CAPTRUST Financial Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,464	Closed	-$15.8K	–	2825
2025 Q3	$15.8K	Sell	10,464 -1,378	-12%	-$2.07K	﹤0.01%	2613
2025 Q2	$13.7K	Sell	11,842 -4,103	-26%	-$5.41K	﹤0.01%	2486
2025 Q1	$25.4K	Buy	15,945 +5,162	+48%	+$11.1K	﹤0.01%	2312
2024 Q4	$32.7K	Buy	+10,783	New	+$35.3K	﹤0.01%	2260
2022 Q3	–	Sell	-750	Closed	-$21K	–	4131
2022 Q2	$21K	Sell	750 -13	-2%	-$344	﹤0.01%	3353
2022 Q1	$35K	Buy	763 +758	+15,160%	+$40.9K	﹤0.01%	3051
2021 Q4	$0	Buy	+5	New	+$387	﹤0.01%	4941
2021 Q1	–	Sell	-385	Closed	-$20K	–	4489
2020 Q4	$20K	Buy	+385	New	+$17.4K	﹤0.01%	2259

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAPTRUST Financial Advisors's ZNTL Position: Q4 2025 in Review

CAPTRUST Financial Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 10,464 shares — an estimated $15.8K sold.

CAPTRUST Financial Advisors first reported a position in ZNTL in Q4 2020 and held it in 8 quarters. The position peaked at $35K in Q1 2022. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

CAPTRUST Financial Advisors reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
CAPTRUST Financial Advisors sold 10,464 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $15.8K.
CAPTRUST Financial Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 8 quarters.
CAPTRUST Financial Advisors's Zentalis Pharmaceuticals position peaked at $35K in Q1 2022.
86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.